OSR (NASDAQ:OSRH) Downgraded to Strong Sell Rating by Wall Street Zen
by Jessica Moore · The Cerbat GemWall Street Zen cut shares of OSR (NASDAQ:OSRH – Free Report) from a sell rating to a strong sell rating in a research report sent to investors on Sunday.
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of OSR in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on OSR
OSR Stock Performance
NASDAQ:OSRH opened at $0.54 on Friday. The firm has a market cap of $17.72 million, a price-to-earnings ratio of -0.42 and a beta of 0.59. OSR has a 12-month low of $0.38 and a 12-month high of $1.79. The company’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.58.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP purchased a new stake in OSR Holdings, Inc. (NASDAQ:OSRH – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 55.30% of the company’s stock.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.